Drug Profile


Alternative Names: 561679; CRF1-antagonist - GSK/Neurocrine; GSK-561679; NBI-77860

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Neurocrine Biosciences
  • Developer GlaxoSmithKline; Neurocrine Biosciences
  • Class Antidepressants; Anxiolytics; Azabicyclo compounds; Oxadiazoles; Pyrazoles; Pyrimidines; Small molecules
  • Mechanism of Action Corticotropin releasing factor receptor 1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Congenital adrenal hyperplasia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alcoholism; Congenital adrenal hyperplasia; Post-traumatic stress disorders
  • No development reported Major depressive disorder; Social phobia
  • Discontinued Irritable bowel syndrome

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 08 Jun 2015 Neurocrine Bioscience suspends a phase I/II trial in Congenital adrenal hyperplasia (In adolescents) in USA prior to enrolment
  • 09 Feb 2015 Neurocrine Biosciences has patent protection for verucerfont in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top